Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

RIDGEFIELD, Conn., Sept. 10, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the completion of patient enrollment for a Phase 2a clinical trial (NCT01859962) investigating a new interferon-free, all-oral, direct-acting antiviral (DAA) combination treatment for patients with genotype-1a chronic hepatitis C virus (HCV) infection. This trial is conducted in collaboration with Presidio Pharmaceuticals, Inc. and evaluates Boehringer Ingelheim's investigational compounds, the protease inhibitor faldaprevir (BI 201335) and non-nucleoside NS5B polymerase inhibitor, deleobuvir (BI 207127), in combination with Presidio's investigational pan-genotypic NS5A inhibitor, PPI-668, with and without ribavirin.

The trial includes 36 treatment-naive genotype-1a infected patients treated for 12 weeks with this all-oral DAA regimen, with 24 weeks of post-treatment follow-up.  The primary endpoint of the trial is sustained virologic response 12 weeks after treatment is completed (SVR12). This Phase 2a trial of a novel combination therapy is a part of Boehringer Ingelheim's commitment to develop new, tailored interferon and ribavirin-free HCV regimens for a broad range of HCV patients.

In March 2013, the two companies entered a non-exclusive collaboration to evaluate the three DAAs in combination regimens. Both companies will retain all rights to their respective compounds. Presidio has operational responsibility for this collaborative trial, with oversight by an intercompany project team. Final results are expected in Q2 2014.

"We are proud to announce that we have completed enrollment in this collaborative trial designed to investigate an all-oral combination of compounds to treat patients with HCV. This further compliments our ongoing Phase 3 HCVerso® trial
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... MARLBOROUGH, Mass. , March 27, 2015 ... ) and privately-held MirImmune LLC, today announced ... license agreement to RXi,s novel and proprietary ... cell-based cancer immunotherapies. The collaboration has the ... and patient friendly cancer treatments that could ...
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
(Date:3/26/2015)... 2015 Huntington Memorial Hospital is the first ... aortic valve replacement (TAVR), a minimally invasive replacement of ... way to replace an aortic valve without a chest ... The procedure is performed by a dedicated ... Alex) Durairaj , MD, interventional cardiologist and Robbin ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
... (OTC Bulletin Board: SNDZ ), announced today that ... with key brokers and funds.  The purpose of these meetings ... to facilitate funding for Sunridge to execute its business plan ... for this project," states G. Richard Smith, CEO of Sunridge. ...
... NEW YORK, Aug. 24 Regenicin, ... a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, ... has agreed to join the company,s board of directors. ... efforts of PermaDerm™, Regenicin,s proprietary autologous cultured ...
Cached Medicine Technology:Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors 2
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... sleep leads to excessive daytime sleepiness, altered mood, and ... accidents. A recent study suggests that obese and overweight ... . ,For the study researchers examined patients' total ... body mass index. More than 1,000 patients completed a ...
... the reason some adolescents experience depression could be abnormal ... between ages 13 to 18, half of who had ... was performed to measure the volume of each teen’s ... hippocampus of patients with depression was, on average, 17 ...
... studies have shown inhaled corticosteroids can reduce the mortality ... results from a study conducted by researchers from the ... than 2,650 patients with COPD who were prescribed inhaled ... period. Nearly 5,400 patients who had never used inhaled ...
... series of laboratory experiments, researchers say they have now ... oil fights cancer.// ,Oleic acid dramatically cut ... of Her-2/neu are associated with aggressive tumors in many ... boosts the effectiveness of the antibody treatment trastuzumab (Herceptin), ...
... world is infected with tuberculosis every second and someone dies ... have discovered easier tests to detect this deadly disease in ... generally done with a gastric lavage. It's an invasive test ... a sputum sample. Sputum is what comes up when you ...
... study shows men who consume three or more alcoholic drinks ... ischemic stroke develops // when an artery in the brain ... than 38,000 participants for 14 years. The male participants responded ... identified 412 cases of ischemic stroke among the study participants. ...
Cached Medicine News:
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... Used for stenting the urethra after ... provide postoperative drainage of the bladder. ... is of sufficient length to allow ... diaper, keeping the inside diaper dry ...
Medicine Products: